Eve image

Consumer Health Data Privacy Policy

STAAR SURGICAL CONSUMER HEALTH DATA PRIVACY POLICY

Last Updated: October 30, 2026

INTRODUCTION

STAAR Surgical Company and our global subsidiaries and affiliates (collectively, “STAAR,” “we,” “us,” and “our”) are committed to respecting your privacy. This Consumer Health Data Privacy Policy supplements the STAAR Surgical Privacy Policy and applies to personal data defined as “consumer health data” subject to the Washington State My Health My Data Act. 

CONSUMER HEALTH DATA COLLECTED

Consumer health data means personal information that is linked or reasonably linkable to a consumer and that identifies the consumer’s past, present, or future physical or mental health status. The consumer health data we collect depends on the context of your interaction with us. Examples of consumer health data we may collect in the course of providing our services include information about an individual’s:

  • health conditions, treatment, diseases, or diagnoses (e.g., vision disorders);
  • medical interventions;
  • use or purchase of medications or prescribed medications;
  • measurements of health information (e.g., eye measurements);
  • diagnoses or diagnostic testing, treatment, or medication; or
  • information that could identify an individual seeking health care services or information. 

SOURCES OF CONSUMER HEALTH DATA

We collect consumer health data from the following sources:

  • directly from you when you interact with us or use our services;
  • automatically through cookies and other tracking technologies that reveal your interest in our services; or
  • from third parties such as healthcare providers who provide health data to us pursuant to your authorization.

PURPOSES FOR COLLECTION AND USE

Our collection of consumer health data is necessary for the provision of our services. In addition, we may use consumer health data to compile analytics, improve our services, comply with legal and regulatory obligations, for any other purpose with your consent, or otherwise as described in the STAAR Surgical Privacy Policy.

DISCLOSURE OF CONSUMER HEALTH DATA

In addition to sharing consumer health data with our service providers, we may share consumer health data with the following third parties:

  • Our affiliates listed in Annex I below.
  • Certain third parties with your consent or at your direction. These parties may include healthcare providers.
  • Other third parties to protect our rights, defend or pursue a legal claim, or investigate or prosecute illegal activities.
  • Government or judicial authorities or agencies to comply with a subpoena, court order, governmental inquiry, legal process, legal obligation, or to protect the rights, property, or safety of other users or the public, including mandatory disclosures to public health authorities or adverse event reporting to regulatory agencies.

We may also share consumer health data with a successor entity or purchaser upon a merger, consolidation, or other corporate reorganization in which we participate, or pursuant to a financing arrangement. 

YOUR RIGHTS

Washington residents have the following rights with respect to their consumer health data, subject to certain exceptions:

  • the right to confirm whether we process your consumer health data, and to access and receive a copy of your consumer health data;
  • the right to a list of all third parties and affiliates with whom we have shared or sold your consumer health data and an email address or other online mechanism that you can use to contact each third party;
  • the right to delete your consumer health data; and
  • the right to withdraw consent to the collection, sharing, or selling of consumer health data.

You can submit a request to exercise these rights using any of the mechanisms listed in the “Contact Information” section below. Depending on the type of request, we may need to verify your request before we can fulfill it. Please note that certain exceptions may apply to these rights (e.g., we may be unable to honor a request to delete if it conflicts with a legal obligation to retain data). Finally, please review the STAAR Surgical Privacy Policy for additional rights and choices you may have with respect to your personal data more generally.

You have the right to appeal any decisions we make in response to a rights request. If your appeal is unsuccessful, you can raise a concern or lodge a complaint with the Washington State Attorney General at www.atg.wa.gov/file-complaint.

 

CHANGES TO THIS POLICY

We may revise this policy from time to time. When we make changes to this policy, we will post the updated version on our website and indicate the date the policy was last updated. We encourage you to review this policy periodically to check for any updates.

CONTACT INFORMATION

If you have questions or concerns regarding this policy or wish to exercise your privacy rights, please contact us at:

STAAR Surgical Company

25510 Commercentre Drive, Ste. 200, Lake Forest, California 92630, USA

Phone: 1.626.303.7902

Email: PrivacyOffice@staar.com

SUPPLEMENT TO CONSUMER HEALTH DATA PRIVACY POLICY FOR NEVADA CONSUMERS

This supplement to our Consumer Health Data Privacy Policy applies to Nevada residents for purposes of providing additional disclosures required by Nevada’s consumer health data privacy law (Nevada Senate Bill 370).

The foregoing consumer health data disclosures and rights also apply to Nevada residents. In addition, Nevada residents also have the right to review and amend any consumer health data we maintain about them. Nevada residents can escalate unsuccessful appeals of consumer rights requests to the Nevada attorney general at https://ag.nv.gov/Complaints/CSU_Complaints___FAQ/. Third parties may collect consumer health data over time and across different websites when you use our websites.

ANNEX I: LIST OF RELEVANT STAAR ENTITIES

  1. STAAR Surgical Company (Delaware, United States)
  2. STAAR Surgical AG (Nidau, Switzerland)

주요 안전성 정보

ICL은 성인을 대상으로 -0.5D에서 -18.0D 범위의 근시와 6.0D까지의 난시 교정에 대해 승인되었습니다. 21세에서 60세 사이의 성인이 ICL 수술 대상이 됩니다. 안내렌즈삽입술의 성공적인 결과를 위해서는 지난 1년간 시력에 변화가 없어야 합니다. ICL 수술은 안경 및 콘택트렌즈 사용이 필요하지 않도록 시력을 교정합니다. 눈의 노화로 인해 자연적으로 필요한 돋보기 안경은 ICL 안내렌즈삽입술을 받은 후에도 필요할 수 있습니다. ICL은 라식(LASIK), 굴절교정레이저각막절제술(PRK) 및 절개 수술을 포함한 다른 굴절 교정수술법들과 콘택트렌즈 및 안경 등의 시력 교정 방법에 대한 대안이 될 수 있습니다. ICL 안내렌즈삽입술은 외과적 수술이므로 심각한 부작용을 유발할 수도 있습니다. 일반적인 굴절 교정 수술과 관련하여 보고된 발생 가능한 부작용 및 합병증에는 추가적 수술, 백내장 발생, 최대교정시력 손실, 안압 증가, 각막내피세포 손실, 결막 자극, 급성 각막 부종, 지속적 각막 부종, 안내염, 빛번짐, 눈부심, 전방출혈(안구 내 출혈), 전방 축농(안구 내 고름), 염증, 렌즈 탈구, 황반 부종, 동공 무반응, 동공차단 녹내장, 심각한 안내 염증, 홍채염, 포도막염, 유리체 손실 및 각막 이식 등이 있습니다. ICL 수술을 고려하기 전, 정밀 눈 검사를 받은 후 안과 전문의에게 ICL 수술의 장점, 위험요소 및 부작용에 대해 상담 하십시오. 수술 후 회복을 위한 시간에 대해서도 상담하십시오.

참고문헌

Locale Switcher

Europe

AustriaBelgium - DutchBelgium - FrenchFranceGermanyItalyNetherlandsNorwayPortugalSpainSwedenSwitzerlandUK & Ireland

North America

CanadaCanada - FrenchMexicoUnited StatesUnited States - 中文

Latin America

Spanish (Mexico)Brazil

North Africa

ArabicFrench

Middle East

Middle East عربىMiddle East - فارسيMiddle East - EnglishTest - English

Asia Pacific

AustraliaChina - 中国IndiaJapan - 日本New ZealandS. Korea - 대한민국South East Asia

Important Safety Information

AlgeriaBahrainIraqJordanKuwaitLebanonLibyaMoroccoOmanQatarSaudi ArabiaSyriaTunisiaUnited Arab EmiratesYemen

참고자료

Home - 광고심의필: 조합-2022-04-030 (유효기간: 2025.02.07)

1. Gonzalo Carracedo, et al. The role of dinucleoside polyphosphates on the ocular surface and other eye structures. Prog Retin Eye Res. 2016 Nov;55:182-205. 2. Paul J Dougherty, et al. Refractive outcomes and safety of the implantable collamer lens in young low-to-moderate myopes. Clin Ophthalmol. 2017;11:273–277. 3. Gregory D. Parkhurst, et al. Phakic Intraocular Lens Implantation in United States Military Warfighters: A Retrospective Analysis of Early Clinical Outcomes of the EVO ICL. J Refract Surg. 2011;27(7);473-481. 4. Feingold et al. Biocompatible, optically transparent, ultraviolet light absorbing, polymeric material based upon collagen and method of making. USPTO June 8, 1999. 5. ICL in Treatment of Myopia (ITM) Study Group. Postoperative Inflammation after Implantation of the Implantable Contact Lens. Ophthalmology 2003;110:2335-2341. 6. Steven Schallhorn, MD et al. Night Driving Simulation in a Randomized Prospective Comparison of Visian Toric Implantable Collamer Lenses and Conventional PRK for Moderate to High Myopic Astigmatism. Journal of Refractive Surgery Vol.26, No. 5, 2010:321-326 7. Gregory D Parkhurst. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clinical Ophthalmology 2016;10:1209-1215. 8. Donald R Sanders et al. United States Food and Drug Administration Clinical Trial of the Implantable Collamer Lens (ICL) for Moderate to High Myopia Three-Year Follow-up. Ophthalmology. 2004;111:1683–1692. 9. Elena Martines-plaze, et al. Effect of the EVO + Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life. Am J Ophthalmol. 2021;226:117-125. 10. Data on file. STAAR Surgical Annual Report.

이보 ICL이란? - 광고심의필: 조합-2022-04-031 (유효기간: 2025.02.07)

1. Feingold et al. Biocompatible, optically transparent, ultraviolet light absorbing, polymeric material based upon collagen and method of making. USPTO June 8, 1999. 2. ICL in Treatment of Myopia (ITM) Study Group. Postoperative Inflammation after Implantation of the Implantable Contact Lens. Ophthalmology 2003;110:2335-2341. 3. Risto J. Uusitalo, et al. Implantable contact lens for high myopia. J Cataract Refract Surg 2002(28):29-36. 4. Gregory D. Parkhurst, et al. Phakic Intraocular Lens Implantation in United States Military Warfighters: A Retrospective Analysis of Early Clinical Outcomes of the EVO ICL. J Refract Surg. 2011;27(7);473-481. 5. FDA. Before, During & After Surgery. https://www.fda.gov/medical-de... (as of 2021-12-24) 6. 윤재문 외. 난시교정용 후방 유수정체 안내렌즈 삽입술의 단기간 임상성적. 대한안과학회지. 2009;50(6):839-851. 7. Steven Schallhorn, MD et al. Night Driving Simulation in a Randomized Prospective Comparison of Visian Toric Implantable Collamer Lenses and Conventional PRK for Moderate to High Myopic Astigmatism. Journal of Refractive Surgery Vol.26, No. 5, 2010:321-326. 8. Gregory D Parkhurst. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clinical Ophthalmology 2016;10:1209-1215. 9. Donald R Sanders et al. United States Food and Drug Administration Clinical Trial of the Implantable Collamer Lens (ICL) for Moderate to High Myopia Three-Year Follow-up. Ophthalmology. 2004;111:1683–1692.

이보 ICL의 장점(야간시력 개선) - 광고심의필: 조합-2022-04-032 (유효기간: 2025.02.07)

1. Steven Schallhorn, MD et al. Night Driving Simulation in a Randomized Prospective Comparison of Visian Toric Implantable Collamer Lenses and Conventional PRK for Moderate to High Myopic Astigmatism. Journal of Refractive Surgery Vol.26, No. 5, 2010:321-326. 2. Gregory D Parkhurst. A prospective comparison of phakic collamer lenses and wavefront-optimized laser-assisted in situ keratomileusis for correction of myopia. Clinical Ophthalmology 2016;10:1209-1215. 3. Donald R Sanders et al. United States Food and Drug Administration Clinical Trial of the Implantable Collamer Lens (ICL) for Moderate to High Myopia Three-Year Follow-up. Ophthalmology. 2004;111:1683–1692. 4. FDA. Before, During & After Surgery. https://www.fda.gov/medical-de... (as of 2021-12-24) 5. 윤재문 외. 난시교정용 후방 유수정체 안내렌즈 삽입술의 단기간 임상성적. 대한안과학회지. 2009;50(6):839-851.

이보 ICL의 장점(안구건조증이 걱정되세요?) - 광고심의필: 조합-2022-04-033 (유효기간: 2025.02.08)

1. Gregory D. Parkhurst, et al. Phakic Intraocular Lens Implantation in United States Military Warfighters: A Retrospective Analysis of Early Clinical Outcomes of the EVO ICL. J Refract Surg. 2011;27(7);473-481. 2. FDA. Before, During & After Surgery. https://www.fda.gov/medical-de... (as of 2021-12-24). 3. 윤재문 외. 난시교정용 후방 유수정체 안내렌즈 삽입술의 단기간 임상성적. 대한안과학회지. 2009;50(6):839-851.

이보 ICL의 장점(마치 내 눈 같은 편안함) - 광고심의필: 조합-2022-04-029 (유효기간: 2025.02.03)

1. FDA. Before, During & After Surgery. https://www.fda.gov/medical-de... (as of 2021-12-24). 2. 윤재문 외. 난시교정용 후방 유수정체 안내렌즈 삽입술의 단기간 임상성적. 대한안과학회지. 2009;50(6):839-851.

수술 과정 - 광고심의필: 조합-2022-04-034 (유효기간: 2025.02.03)

1. FDA. Before, During & After Surgery. https://www.fda.gov/medical-de... (as of 2021-12-24) 2. 윤재문 외. 난시교정용 후방 유수정체 안내렌즈 삽입술의 단기간 임상성적. 대한안과학회지. 2009;50(6):839-851. 3. Elena Martines-plaze, et al. Effect of the EVO + Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life. Am J Ophthalmol. 2021;226:117-125. 4. Data on file. STAAR Surgical Annual Report.

자주 묻는 질문 - 광고심의필: 조합-2022-04-035 (유효기간: 2025.02.03)

1. Feingold et al. Biocompatible, optically transparent, ultraviolet light absorbing, polymeric material based upon collagen and method of making. USPTO June 8, 1999. 2. ICL in Treatment of Myopia (ITM) Study Group. Postoperative Inflammation after Implantation of the Implantable Contact Lens. Ophthalmology 2003;110:2335-2341. 3. Risto J. Uusitalo, et al. Implantable contact lens for high myopia. J Cataract Refract Surg 2002(28):29-36. 4. Elena Martines-plaze, et al. Effect of the EVO + Visian Phakic Implantable Collamer Lens on Visual Performance and Quality of Vision and Life. Am J Ophthalmol. 2021;226:117-125.

개인정보 수집 및 이용

이보 ICL 브로슈어 발송을 위한 최소한의 개인정보를 수집하고 이용합니다.

수집된 정보는 이메일 발송 외 다른 목적으로 이용되지 않으며, 서비스가 종료되거나 구독을 해지할 경우 즉시 파기됩니다.